CD8A and acute myeloid leukemia: In another recent study, Mazziotta et al. provided a detailed characterization of CD8+ T cell populations in AML patients undergoing standard chemotherapy treatment at baseline and after treatment; patients achieving a complete response were classified as responders and the others not achieving a complete response as non-responders [145].